The Pennant Group, Inc. (PNTG) vs Ultragenyx Pharmaceutical Inc. (RARE)
A side-by-side comparison of The Pennant Group, Inc. and Ultragenyx Pharmaceutical Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PNTG
The Pennant Group, Inc.
$40.72HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
RARE
Ultragenyx Pharmaceutical Inc.
$14.63HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
Total return — PNTG vs RARE
growth of $100 · dividends reinvested · last 7yPNTG +167.1% (+15.1%/yr)RARE -65.9% (-14.2%/yr)PNTG compounded faster over this window
Log scale — wide-divergence pair
PNTG RARE
PNTG vs RARE: by the numbers
- •RARE is the larger company ($1.44B vs $1.42B market cap).
- •PNTG is profitable (2.93% net margin) while RARE runs a net loss (-81.79%).
- •PNTG grew revenue faster over the past five years (21.14% vs 14.81% CAGR).
Metrics side by side
Valuation
| Metric | PNTG | RARE |
|---|---|---|
| P/E ratio | 45.25 | N/A |
| Forward P/E | 29.18 | N/A |
| PEG ratio | 4.49 | N/A |
| P/S ratio | 1.29 | 2.01 |
| P/B ratio | 3.94 | N/A |
| EV / EBITDA | 25.70 | N/A |
| FCF yield | 1.84% | N/A |
Profitability
| Metric | PNTG | RARE |
|---|---|---|
| Gross margin | 14.79% | 83.12% |
| Operating margin | 5.77% | -73.77% |
| Net margin | 2.93% | -81.79% |
| ROE | 9.00% | N/A |
| ROIC | 5.22% | -53.48% |
Growth (annualized)
| Metric | PNTG | RARE |
|---|---|---|
| Revenue CAGR (5Y) | 21.14% | 14.81% |
| EPS CAGR (5Y) | 8.96% | N/A |
| Total return CAGR (5Y) | 8.88% | -30.14% |
Frequently asked
- Which has grown faster, PNTG or RARE?
- Over the past five years, PNTG grew revenue faster — PNTG at a 21.14% CAGR versus RARE at 14.81%.
- Is PNTG or RARE more profitable?
- PNTG runs the higher net margin — PNTG at 2.93% versus RARE at -81.79%.
- How have PNTG and RARE total returns compared?
- Over the past 5 years, PNTG delivered 8.88% and RARE delivered -30.14% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Pennant P/E ratioPennant ROEUltragenyx Pharmaceutical ROEPennant operating marginUltragenyx Pharmaceutical operating marginPennant revenue growthUltragenyx Pharmaceutical revenue growthPennant free cash flowUltragenyx Pharmaceutical free cash flow
Pennant & Ultragenyx Pharmaceutical appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.